News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline Starts Two Late-Stage Trials of Melanoma Drugs
January 25, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- British drugmaker GlaxoSmithKline (GSK.L) said on Monday it was starting two global late stage trials of drugs in advanced or metastatic melanoma in patients whose tumours have a particular gene mutation.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
GSK
MORE ON THIS TOPIC
IN PARTNERSHIP WITH GEMPHARMATECH
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
September 2, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Multiple sclerosis
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
September 2, 2026
·
2 min read
·
Tristan Manalac
FDA
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
September 2, 2026
·
2 min read
·
Jef Akst
Cancer
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
September 1, 2026
·
2 min read
·
Annalee Armstrong
